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frequent in the TS group compared with TR group (p = 0.043). A
significant association between IVS7+24G>A SNP and high TGF-
bR1 protein expression was observed (p = 0.044). Nonetheless,
among all studied polymorphisms only ESR12014G>A SNP was
correlated with a heterogeneous distribution of ERa expression
(r = 0.353, p = 0.016).
Conclusion: These data suggest that the distribution pattern of
ERa expression, EGFR expression and ESR1 2014G>A genetic
variation could be useful additional prognostic markers for
hormone receptor-positive breast cancer patients treated with
adjuvant tamoxifen.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.004
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Tumor markers play an important role in the identification of
human malignancies. It has been shown that the carcinoembry-
onic antigen (CEA, CEACAM5) is a promoter of metastasis in
epithelial cancers that is widely used as a clinical marker. The
aim of this study is to elucidate the network of genes that are
involved in the CEA-induced liver metastasis. Previously, we have
shown that CEA is accumulated in the lungs and livers of rats by
interacting with their macrophages. We identified and cloned a
new gene (CEAR) for the CEA-binding protein, which is located
on the surface of fixed liver macrophages, Kupffer cells (Bajenova
et al, 2001). It has been shown that the interaction of CEA and
CEAR proteins increases the production of IL-1, IL-10, IL-6,
TNF-a cytokines (Thomas et al, 2011). This interaction changes
the expression of liver adhesion molecules that enhances the
survival of cancer cells to the liver. We also suggested that CEA
synthesis by cancer cells may influence the E-cadherin adhesion
junction complexes and have shown that CEA production violates
the functional relationship between Ecadherin and its partners a-,
b- and p120 catenin. A new type of interaction was discovered
between the CEA and b-catenin and the increased amount of
b-catenin in the nuclei of CEA producing cells. The data show that
CEA production can cause the dissociation of cancer cells and
trigger cancer progression. The CEA synthesis also alters splicing
of p120 catenin protein and causes the release of soluble
E-cadherin. Previously, CEA and epithelial E-cadherin were
considered as independent tumor markers. Our data explain
the correlation between the elevated levels of CEA and the
increase in soluble E-cadherin in the progression of colorectal
cancer (Bajenova et al, 2014).
We carried out a comparative transcriptome analysis of CEA-
producing cell lines. The RNA transcriptome libraries were
obtained and sequenced. By pairwise comparisons of CEA pro-
ducing and non-producing cell lines using Cummerband pro-
gram, we selected the set of genes (90 total genes) whose
expression have been changed in the CEA-producing cell lines
(overexpressed or downregulated). The biological processes that
are linked to this differential gene expression were identified by
Gene Set Enrichment Analysis (GSEA). In total, 8 significantly
enriched GO terms related to the cellular components and biolog-
ical processes were identified. Using KEGG and GO databases, we
also identified the signaling pathways involved in the response to
CEA. These findings have direct medical application, since they
allow not only to establish the relationships between the existing
biomarkers but also to discover the new ones. These biomarkers
can be used for diagnosis and monitoring of metastatic carcino-
mas and for the drug development.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.005
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Discovery of new pharmacologically active small molecules is
an important and rapidly expanding area of modern molecular
pharmacology. Given a limited number of proteins that are drug-
gable, it is important to identify as many chemical effectors as
possible to define the best regimen of anti-cancer therapy in each
particular case. An E3 ubiquitin ligase, Mdm2, which mediates
ubiquitin-dependent degradation of the critical tumor suppressor
p53, is a promising target for small molecule inhibitors. Using a
hybrid approach which combines the rational design of small
molecules selected from the virtual library and the high-content
screening using cancer cell lines we discovered several new inhi-
bitors of the p53-Mdm2 interaction. These compounds were able
to activate and stabilize the p53 protein causing massive apopto-
sis preferably in p53-positive cells at rates higher than the well-
known inhibitor of Mdm2, Nutlin-3. The molecular mechanisms
of their action will be discussed.
As another example of rational design of potential anti-cancer
drugs, we will talk about artificial nano-Matrix-Imprinted -
Polymers (MIPs) that recognize the structure of peptides and
other biological molecules and thus dubbed as ‘‘plastic antibod-
ies”. We have generated such nanoparticles against the surface
region of the oncogenic receptor, EGFR, which is overexpressed
in many forms of solid tumors. Selection of the linear epitope
for creating ‘‘plastic antibodies” against the receptor was per-
formed by analysis of a three-dimensional structure of the pro-
tein. The obtained ‘‘plastic antibodies” were specific against the
epitope of EGFR. These plastic antibodies when loaded with a
genotoxic drug, doxorubicin, were able to specifically induce cell
death of breast cancer cell lines that overexpress the EGFR recep-
tor. Experiments in vivo using xenografts of breast cancer cell
lines pre-incubated with these plastic antibodies in nude mice
showed that they have a pronounced therapeutic effect. Further-
more, since the commercial drug, Cetuximab, recognizes an epi-
tope of EGFR, different from the one recognized by our plastic
antibodies, it is likely that the latter may increase the efficacy of
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the commercial monoclonal antibody. Collectively, we demon-
strate that the rationally designed small molecules can be potent
and specific drugs for anti-cancer therapy.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.006
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Numerous studies have shown that high-dose chemotherapy
and autologous hematopoietic stem cell transplantation (AHSCT)
led to a profound and long-lasting state of immunodeficiency
characterized by persisting low levels of T cells in hemoblastosis
patients. Well-timed T-cell reconstitution is crucial for early
restoration of anti-infectious and anti- tumor immune response.
Lymphocyte recovery is mediated through the two main mecha-
nisms – a homeostatic proliferation of T cells and generation of
new naive T cells via thymopoiesis. It is known, that homeostatic
proliferation is important for the restoration of T cell count in
immune competent host during the 1st year following AHSCT.
Thymus begins to fill up T cell repertoire approximately from
the 6th month following AHSCT.
We have investigated dynamics of CD4+FOXP3+ Treg recovery
following AHSCT and possible relationship between Tregs and
clinical outcomes since the suppressive activity of Tregs under
lymphopenic conditions may influence on peripheral expansion
of T cells. Thymic activity following AHSCT has been evaluated
by measuring amounts of CD4+ CD45RA+CD31+ naı¨ve T cells,
i.e. ‘‘recent thymic emigrants” (RTEs).109 patients with non-
Hodgkin’s lymphomas, Hodgkin’s lymphoma and multiple mye-
loma underwent AHSCT in 2009–2014. The content of circulating
CD4+FOXP3+ Tregs and CD4+CD45RA+CD31+ T cells was
evaluated using flow cytometry before AHSCT, at the day of
engraftment, and following 6 and 12 months.
Pre-transplant count of CD4+FOXP3+ Tregs was significantly
higher compared to healthy controls (5.4 ± 2.9 vs 3.8 ± 1.9%;
pU = 0.011; here and below data presented as Mean ± SD). Percent-
age of Tregs restored rapidly and reached initially high level at the
time of engraftment, and then subsequently decreased within a
year until it lowered to healthy donors‘ values. CD4+FOXP3+ Tregs
at the time of engraftment were increased in patients with
relapse or progression of disease within 6 and 12 months
following AHSCT compared to non-relapsed patients (11.0 ± 6.1
vs 6.2 ± 3.0%; pU = 0.016, and 10.1 ± 5.2 vs 6.1 ± 3.8%; pU = 0.008).
Pre-transplant count of CD4+CD45RA+CD31+ T cells was signifi-
cantly lower compared to healthy controls (17.1 ± 11.4 vs 30.3
± 11.2%, pU = 0.0005) and did not reach donors‘ values following
12 month (23.1 ± 13.5%, pU = 0.032). Relapsed patients had the
same quantity of RTEs as the patients with remission within
the 1st year following AHSCT. There was no any significant
association between RTEs and Tregs counts.
Surprisingly, we have found high levels of circulating CD4
+CD45RA- T cells co-expressing CD31 molecule in patients before
AHSCT, since this molecule is infrequent on memory subsets in
healthy controls (20.7 ± 12.0 vs 8.2 ± 2.1%,pU < 0.00001). Relative
amount of CD4+CD45RA-CD31+ T cells highly correlated with
CD4+CD45RO+CD31+ population (rS=0.72; p < 0.00001). The count
of CD4+CD45RA-CD31+ T cells recovered intensively and reached
the pre-transplant level within the 1st month following AHSCT,
and remained at the same level throughout the follow-up. There
were no any differences in relative count of CD4+CD45RA-CD31+
T cells between patients with early relapse and remission during
the 1st post-transplant year.
Our data of Tregs reconstitution may confirm the earlier
assumption that the presence of Tregs during the period of
immune recovery preserves optimal T cell receptors diversity.
However, the excess of these cells leads to the inhibition of
proliferative activity and immune response and is associated with
early relapse. Conversely, relatively slow recovery of RTEs
determines theirlack of influence on survival within the 1st
post-transplant year.
The biological role and the way of appearance of CD31
molecule on T cell memory subset (CD4+CD45RA- and/or CD4
+CD45RO+) still remain unclear. Further studies are required to
enlighten the role of CD31+ memory T cells on lymphoprolifera-
tive disorders pathogenesis.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.007
P57
The first Siberian experience of gastric cancer riskometry: Prospective
‘‘case-control” study
A. Belkovetsa,*, S. Kurilovicha,b, O. Reshetnikova, Y. Raginoa,
M. Voevodaa,b. a Federal State Budgetary Scientific Institution
‘‘Institute of Internal and Preventive Medicine”, Novosibirsk, Russian
Federation, bNovosibirsk State Medical University, Russian Federation
⇑
Corresponding author.
Background: Gastric cancer (GC) remains one of the most
important gastrointestinal cancers worldwide. The incidence
and mortality rate from GC in Russia is higher in comparison with
other European countries and USA. It should be noted that
riskometry for the GC doesn’t exist. Parallel assessment of
pepsinogen I (PG I), pepsinogen II (PG II), PG I/PG II ratio and
gastrin-17 (G-17), as well as antibodies to Helicobacter pylori is an
exact and validated set of stomach-specific biomarkers that
reflect the extent and grade of gastric atrophy as a main prema-
lignant condition for GC.
Aim: To study the diagnostic and predicting value of
biomarkers of atrophic gastritis (AG) in retro-prospective cohort
case-control study in Siberian population.
Object and methods: General population sample was surveyed
in Novosibirsk in 2003–2005 (10.000 subjects aged 45–69 years).
Each serum sample was deeply frozen and stored. In 2008 and
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